Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort.

Dear Editor, Innovative therapeutic strategies in metastatic melanoma depend on molecular features and the combination of BRAF and MEK inhibitors (BRAFi+MEKi), which has recently shown an improved clinical efficacy in patients with I BRAF i SP V600MUT sp metastatic melanoma, is now the standard of care. Among them, 21 BRAFi±MEKi-treated patients had at least one sample harbouring I BRAF/NRAS i concurrent mutations ( I n i = 2 primary tumours and I n i = 19 metastases) and were included in this retrospective study after signed informed consent. To provide arguments regarding the potential clinical impact of co-occurrence of I BRAF/NRAS i mutations, patients with I NRAS i SP WT sp ( I n i = 6) and I NRAS i SP MUT sp ( I n i = 12) baseline tumours were compared. [Extracted from the article]